August 25, 2024
Managing Metabolic Disorders Pharmacy CE Conference
Sunday, August 25, 2024
Updates in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Out With the Old in With the New
8:00-9:30am Consultant/General
Erenie Guirguis, Pharm. D., BCPS, FFSHP, Associate Professor of Pharmacy Practice, PGY-1 Residency Program Director, Lloyd L. Gregory School of Pharmacy
Upon completion of this activity, pharmacists will be able to: Discuss the nomenclature change from NAFLD to MASLD to increase disease awareness; Recognize the associated burden of disease due to MASLD in adult patients; Discuss the pathophysiology and clinical presentation of MASLD; Review current national guideline recommendations for the treatment of patients with MASLD; Evaluate recent literature on emerging treatment options and the real-world application for the management of MASLD patients.
UAN: 0675-0000-24-026-L01-P*
Navigating Hypertension Management
9:30-11:00am Consultant/General
Yasmin Grace, B.S., PharmD, Professor of Pharmacy Practice, Palm Beach Atlantic University
Upon completion of this activity, pharmacists will be able to: List factors contributing to the etiology of primary and secondary hypertension; Describe the diagnosis of hypertension and the purpose of ambulatory blood pressure monitoring; Recommend lifestyle modifications for hypertension management and evaluate their efficacy; Describe the current approach to the management of hypertension; Compare and contrast the characteristics of antihypertensive drug classes including place in therapy, adverse effects, drug interactions, contraindications, and monitoring; Design individualized antihypertensive treatment regimens for different patient populations.
UAN: 0675-0000-24-027-L01-P*
From Filtration to Precision: Evolving CKD Therapies
11:15-12:45pm Consultant/General
Erini Serag-Bolos, PharmD, Assistant Dean of Academic Affairs, Associate Professor, Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, Department of Internal Medicine, Morsani College of Medicine
Upon completion of this activity, pharmacists will be able to: Interpret laboratory values of chronic kidney disease (CKD); Develop prevention and treatment plans for patients with metabolic CKD; Discuss medications that may cause CKD and/or require renal dose adjustments.
UAN: 0675-0000-24-028-L01-P*
Managing Metabolic Disorders - The Role of the Pharmacist within the Technological Ecosystem
12:45-2:15pm Consultant/General
Aimon C. Miranda, PharmD, BCPS, Associate Professor, Coordinator of Clinical Informatics, Department of Pharmacotherapeutics and Clinical Research, Taneja College of Pharmacy, Department of Internal Medicine I College of Medicine, University of South Florida and Kevin Olson
Upon completion of this activity, pharmacists will be able to: Define how the technological ecosystem interacts with individuals and organizations; Describe current applications for managing metabolic disorders; Discuss barriers and implications of technology integration.
UAN: 0675-0000-24-029-L01-P
Validation and Counseling of Prescriptions for Controlled Substance & Opioids
2:30-4:30pm General
Joseph Cammilleri, PharmD, BCACP, CPE, Ambulatory Care Clinical Pharmacist, Pain Management, PGY2 Pain/Palliative Care Program Director, UF Health.
Upon completion of this activity, pharmacists will be able to: Describe how to ensure access to controlled substances for all patients with a valid prescription; Use the Prescription Drug Monitoring Program’s Database; Assess prescriptions for appropriate therapeutic value; Detect prescriptions that are not based on a legitimate medical purpose; Discuss the laws and rules related to the prescribing and dispensing of controlled substances; Discuss proper patient storage and disposal of controlled substances; Discuss protocols for addressing and resolving problems recognized during the drug utilization review; Provide education on section 381.887, F.S., emergency treatment for suspected opioid overdoses and on the State Surgeon General’s Statewide Standing Order for Naloxone; Counsel patients with opioid prescriptions; Provide available treatment resources for opioid physical dependence, addiction, misuse, or abuse.
UAN: 0675-0000-24-030-L08-P*
No Comments